B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
KURA
Kura OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
KOMZIFTI has early commercial traction and broad payer access, while ziftomenib's AML combination programs and darlifarnib's FIT-001 development provide multiple potential clinical value inflections. The primary-source operating evidence is constructive, but the Q2 follow-up remains unconfirmed.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.6.
What can break
Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
Momentum
90
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $18.00 · Bear $6.00Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $32.00
Why
Momentum90 · Δ7d +6.4
Value41 · Δ7d 0.0
Sentiment46 · Δ7d +7.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +7.6.
Contradictions & invalidation
- • Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
- • Early KOMZIFTI revenue and prescription activity may not yet demonstrate durable commercial scale or repeat utilization.
- • The investment case remains dependent on clinical execution, enrollment, durability of commercial uptake, and future readouts.
Catalyst clock
2026-07-27
FIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionality
Lead driver: Sentiment · See AI snapshot
Momentum
90
9% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+36.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
46
62% active weight
Current posture
7d trendImproving
Δ7d
+7.6
Δ21d
+0.5
Why this grade
Composite grade D. Momentum 90.0 / Value 41.2 / Sentiment 46.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1B
Beta
0.24
Shares Out
88.96M
P/E (TTM) · Derived
-3.5
P/S (TTM)
7.98
P/FCF (TTM)
9.99
Rev YoY
+36.5%
EPS YoY
+1.9%
Gross Margin
+97.6%
Op Margin
-411.9%
Net Debt
-$646.78M
Current Ratio
4.73
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data